Related Experiment Videos
Identification and characterization of A-105972, an antineoplastic agent.
J R Wu-Wong1, J D Alder, L Alder
1Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA. ruth.r.wuwong@abbott.com
Cancer Research
|March 14, 2001
Summary
A-105972 is a novel compound that inhibits cancer cell growth by interacting with microtubules, causing cell cycle arrest and apoptosis. It shows efficacy against various cancer types, including multidrug-resistant cells, and improves survival in mice.
Area of Science:
- Pharmacology
- Cell Biology
- Oncology
Background:
- High-throughput screening identifies novel anti-cancer agents.
- Cancer cell proliferation is a major therapeutic challenge.
- Multidrug resistance (MDR) limits treatment efficacy.
Purpose of the Study:
- To identify and characterize novel small molecules that inhibit cancer cell growth.
- To investigate the mechanism of action of the identified compound A-105972.
- To evaluate the anti-cancer efficacy of A-105972 in vitro and in vivo.
Main Methods:
- High-throughput screening of over 60,000 compounds.
- Cytotoxicity assays (IC50 determination) across various cancer cell lines.
- Cell cycle analysis (G2-M phase arrest).
- Tubulin binding assays using radiolabeled compound.
- Microtubule arrangement and apoptosis studies.
- In vivo efficacy studies in tumor-bearing mice.
Main Results:
- A-105972 identified as a potent inhibitor of breast, CNS, colon, liver, lung, and prostate cancer cell lines (IC50: 20-200 nM).
- A-105972 binds to tubulin, arrests cells in G2-M phase, and induces apoptosis.
- Compound is effective against multidrug-resistant cells and p53-mutant cells.
- A-105972 treatment increased survival in mice bearing melanoma, leukemia, and MDR leukemia.
Conclusions:
- A-105972 is a promising anti-cancer agent targeting microtubules.
- It effectively inhibits cancer cell proliferation and induces apoptosis.
- A-105972 demonstrates potential for treating diverse cancers, including MDR types.